Pfizer is Pulling Celebrex® Ads

Return to Celebrex® homepage on SSEM.COM

According to Pfizer spokesperson Andy McCormick, Pfizer will be pulling Celebrex® ads from newspapers, radio, TV and magazines. This comes just days after the National Cancer Institute found that patients taking 400 and 800 mg doses of the top-selling arthritis drug were more susceptible to cardiovascular problems.

Pfizer will also be meeting with physicians to discuss the findings. The company is also in discussions with the FDA about the findings and possible new warning labels that could be instituted.

For the first nine months of 2004 sales of Celebrex® were $2.3 billion, accounting for 6 percent of Pfizer's total sales. In 2003, the total marketing expense on Celebrex® was $87.6 million. The company recently launched a new campaign after the withdrawl of Vioxx®, one it's main competitors, from the market by Merck & Co.

If you believe that you or a relative were injured by taking Celebrex® please use the form below to contact our law firm.

Have you suffered a heart attack or stroke? (Select Yes or No)
YES
NO

Your Name:

Your E-Mail:

Your Daytime Phone Number:

Your Evening Phone Number:

Please fill in your question or comments:

References

Copyright © 1999-2008 Specter Specter Evans & Manogue, P.C.
Terms of Use | Privacy Policy